Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, arising almost exclusively in the setting of chronic liver disease or cirrhosis. Treatment has been transformed by immune checkpoint inhibitor combinations: atezolizumab + bevacizumab (IMbrave150) is the first-line standard, with lenvatinib and sorafenib as alternatives, and regorafenib, cabozantinib, and ramucirumab available in later lines.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Hepatocellular Carcinoma

• Atezolizumab (Tecentriq) — Checkpoint Inhibitor
• Bevacizumab (Avastin) — Monoclonal Antibody
• Lenvatinib (Lenvima) — Tyrosine Kinase Inhibitor
• Sorafenib (Nexavar) — Tyrosine Kinase Inhibitor
• Durvalumab (Imfinzi) — Checkpoint Inhibitor
• Nivolumab (Opdivo) — Checkpoint Inhibitor
• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Regorafenib (Stivarga) — Tyrosine Kinase Inhibitor
• Cabozantinib (Cabometyx) — Tyrosine Kinase Inhibitor
• Ramucirumab (Cyramza) — Monoclonal Antibody